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Context: The safety of insulin in the treatment of type 2 diabetes mellitus (T2DM) has recently
undergone scrutiny.
Objective: The objective of the studywas to characterize the risk of adverse events associatedwith
glucose-lowering therapies in people with T2DM.
Design and Setting: This was a retrospective cohort study using data from the UKGeneral Practice
Research Database, 2000–2010.
Patients: Patients comprised 84 622 primary care patients with T2DM treated with one of five
glucose-lowering regimens: metformin monotherapy, sulfonylurea monotherapy, insulin mono-
therapy, metformin plus sulfonylurea combination therapy, and insulin plus metformin combina-
tion therapy. There were 105 123 exposure periods.
Main Outcome Measures: The risk of the first major adverse cardiac event, first cancer, or mortality
was measured. Secondary outcomes included these individual constituents and microvascular
complications.
Results: In the samemodel, andusingmetforminmonotherapyas the referent, theadjustedhazard
ratio (aHR) for the primary end point was significantly increased for sulfonylurea monotherapy
(1.436, 95% confidence interval [CI] 1.354–1.523), insulin monotherapy (1.808, 95% CI 1.630–
2.005), and insulin plus metformin (1.309, 95% CI 1.150–1.491). In glycosylated hemoglobin/mor-
bidity subgroups, patients treated with insulin monotherapy had aHRs for the primary outcome
ranging from 1.469 (95% CI 0.978–2.206) to 2.644 (95% CI 1.896–3.687). For all secondary out-
comes, insulin monotherapy had increased aHRs: myocardial infarction (1.954, 95% CI 1.479–
2.583), major adverse cardiac events (1.736, 95% CI 1.441–2.092), stroke (1.432, 95% CI 1.159–
1.771), renal complications (3.504, 95% CI 2.718–4.518), neuropathy (2.146, 95% CI 1.832–2.514),
eye complications (1.171, 95% CI 1.057–1.298), cancer (1.437, 95% CI 1.234–1.674), or all-cause
mortality (2.197, 95% CI 1.983–2.434). When compared directly, aHRs were higher for insulin
monotherapy vs all other regimens for the primary end point and all-cause mortality.
Conclusions: InpeoplewithT2DM,exogenous insulin therapywasassociatedwithan increased risk
of diabetes-related complications, cancer, and all-cause mortality. Differences in baseline charac-
teristics between treatment groups should be considered when interpreting these results. (J Clin
Endocrinol Metab 98: 668–677, 2013)
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The primary aim of diabetes management is theachievement and maintenance of normoglycemia
(1). The importance of glucose control in reducing vas-
cular outcomes is well known (2). However, the prolif-
eration of new diabetes therapies and a spotlight on the
safety profile of once-common therapies have led to
debate about what the optimum target level of control
should be (3–5).
Current guidelines recommend metformin mono-
therapy after the failure of diet and exercise in type 2
diabetes (6). If blood glucose levels become difficult to
maintain on metformin monotherapy, it is recom-
mended that a sulfonylurea be added to the regimen or,
in the case of contraindication, a dipeptidyl peptidase-4
inhibitor or a thiazolidinedione. After this, the guide-
lines become more complex, attempting to balance glu-
cose control with other factors such as weight gain and
hypoglycemia, reflecting the limited evidence compar-
ing different regimens.
Exogenous insulin is one of themost established blood-
glucose-lowering therapies, and its use in peoplewith type
2 diabetes mellitus (T2DM) has grown markedly over re-
cent years (7), consequent upon findings from theUKPro-
spective Diabetes Study and the availability of analog in-
sulins that have increased comfort with insulin initiation
and titration. Indeed, we have recently estimated that, in
the United Kingdom, the number of people with T2DM
treated with insulin increased from 37 000 in 1991 to
277 000 in 2010 (Holden, SE, unpublished data). Early
insulization has recently been recommended in guidelines
from the American Diabetes Association and European
Association for the Study of Diabetes (8), but the risk–
benefit profile of exogenous insulin in the management of
people with T2DM has also undergone scrutiny (9–12).
Initial concerns regarding theutility of insulin inT2DM
emerged from epidemiological data characterizing the
mortality impact of insulin froma large, population-based
study in Canada, in which a dose–response relationship
was observed between insulin use and all-cause mortality
(13). The investigators reported a three-fold increase in
mortality in the highest-exposure group. Similarly, in an
epidemiological studyof peoplewithT2DMtreated inUK
primary care, those treated with insulin had a 50% in-
creased mortality compared with those managed with a
combination of metformin plus sulfonylurea (14). Other
large-scale observational studies have reported a 2.5-fold
increased risk of cardiac events in insulin-treated people
with T2DM (15, 16). Insulin therapy has been related to
increased mortality in people with T2DM complicated by
advanced heart failure (17).
Potential mechanisms that may account for any rela-
tionship between exogenous insulin and adverse vascular
outcomes in people with T2DM include cardiac arrhyth-
mia leading to sudden death as a consequence of hypo-
glycemia (18), inflammation (19), and coagulation (20).
Simultaneously, the link between insulin therapy and can-
cer is under considerable scrutiny (21, 22).
In view of these considerations, our objective was to
compare the clinical outcomes of people with T2DM
treated with insulin with those in patients treated with
other glucose-lowering regimens.
Materials and Methods
Ethics statement
Studies using the General Practice Research Database
(GPRD) are covered by ethics approval granted by the Trent
Multicentre Research Ethics Committee (reference 05/MRE04/
87). This study was granted GPRD Independent Scientific Ad-
visory Committee approval (ISAC 11-17).
Design
The study used a retrospective-cohort design using data from
the GPRD (replaced by the Clinical Practice Research Datalink
from March 2012), a longitudinal, anonymized research data-
basederived fromnearly600primary carepractices in theUnited
Kingdom (23). The GPRD database contained records for more
than 10 million people, of whom approximately 5 million were
actively registeredandcouldbe followedupprospectively.Avail-
able data included demographics, medical history (including di-
agnoses and health contacts), clinical investigation results, and
prescriptions. Diagnostic information in GPRD was recorded
using the Read code classification, a UK general-practice stan-
dard. For the purposes of this study, data were selected from
January 1, 2000, to December 31, 2010.
Patient selection
All patients were required to be incident cases based on a
wash-in period of at least 180 days between the subject’s regis-
tering at the practice and their first record of diabetes (either first
diabetes diagnosis or first glucose-lowering prescription).
A diagnosis of T2DM was defined by one or more of the
following decision rules: 1) more than one diagnosis recorded
exclusively for T2DM; 2) prescription of two or more differing
classes of oral antidiabetic drug; or 3) a diagnostic code indica-
tive of T2DM (regardless of a conflicting diagnosis of type 1 or
nonspecific diabetes) plus a prescription for an oral antidiabetic
drug. Patients with diagnoses of both type 1 and type 2 diabetes
in their patient record and an age at diagnosis of less than 35
years were defined as type 1 diabetes and therefore excluded.
Glucose-lowering regimen cohorts
Patients were defined by treatment cohorts based on the cri-
teria of a minimum exposure of 180 days on the same glucose-
lowering regimen. Glucose-lowering regimens were grouped in
the following cohorts: metformin monotherapy, sulfonylurea
monotherapy, insulin monotherapy, metformin plus sulfonyl-
urea combination therapy, and insulin plus metformin combi-
nation therapy. Patients could be included in multiple cohorts if
they switched regimens during the study period.
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Clinical end points
In addition to death, six clinical outcomeswere defined by the
Read code recorded within the patient record (see Supplemental
Appendix 1, published on The Endocrine Society’s Journals On-
line web site at http://jcem.endojournals.org). These were: 1)
MACE (major adverse cardiac event), defined as nonfatal myo-
cardial infarction (MI), nonfatal ischemic or hemorrhagic
stroke,or cardiovasculardeath;2) cancer, including solid tumors
and hematological forms; 3) visual deterioration, including
blindness, retinopathy, and glaucoma; 4) diabetic neuropathy;
and 5) renal failure. The primary end point of this study was the
occurrence of the first of the three major clinical outcomes: all-
cause mortality, incident cancer, or MACE. Cases with a prior
history of large-vessel disease (LVD) and/or cancer were
excluded.
The secondary end points of the study were the individual
components of the primary end point and the microvascular
complications. For each analysis, patients with a prior history of
the relevant morbidity were excluded. In addition, for the anal-
ysis of renal impairment, patients with baseline serum creatinine
above the normal range were excluded.
Statistical analysis
Outcome riskwas compared usingCoxproportional hazards
models from the index date to the date of an outcome event.
Cases were censored either at the date of switching to an alter-
native glucose-lowering regimenor at the person’s final recorded
data. For each outcome, the adjusted hazard ratio is given with
the 95% confidence interval (CI). The proportional hazards as-
sumption was tested by examining the Pearson correlation be-
tweenSchoenfeld residuals and the rankof survival time for cases
that progressed to an event. Baseline differences between cohorts
were assessed by univariate analysis appropriate to the distribu-
tion of the parameter; however, differences were expected but
accounted for using multivariate models. For the main analyses,
metformin monotherapy was selected as the reference glucose-
lowering regimen.Twoadditional analyseswere performed.The
first compared all therapies to insulin monotherapy for the pri-
mary and secondary end points. The second compared insulin to
metformin for patients stratified by tertiles of baseline glycosy-
lated hemoglobin (HbA1c) and baseline morbidity as measured
by theCharlsoncomorbidity index (24)definedas low(Charlson
index  1) or high (Charlson index 1).
Table 1. Baseline Characteristics
Parameter All Subjects Metformin Sulfonylurea
Metformin
 Sulfonylurea Insulin
Insulin
 Metformin
Number of persons, n (%) 105 123 58 532 (53.4) 16 218 (14.8) 23 049 (21.0) 3944 (3.6) 3380 (3.1)
Follow-up, total (mean), y 298 530 (2.8) 163 790 (2.8) 44 712 (2.8) 65448 (2.8) 12 842 (3.3) 11 738 (3.5)
Age, mean (median), ya 61.9 (12.8) 60.7 (12.6) 68.1 (12.6) 61.5 (12.1) 61.3 (14.5) 57.6 (11.9)
Males, n (%) 59 378 (56.5) 32 700 (55.9) 8817 (54.4) 13 840 (60.0) 2083 (52.8) 1938 (57.3)
HbA1c, mean (SD), %b 8.7 (1.9) 8.5 (1.9) 8.7 (2.1) 9.0 (1.8) 9.5 (2.2) 9.6 (1.8)
SBP prior, mean (SD),
mm Hgb
138.8 (17.9) 139.3 (17.5) 139.6 (19.8) 137.9 (17.3) 134.6 (19.9) 136.2 (17.0)
Smoked ever, n (%) 62 969 (59.9) 34 862 (59.6) 9283 (57.2) 14 189 (61.6) 2444 (62.0) 2191 (64.8)
TC prior, mean (SD),
mmol/Lb
4.9 (1.3) 5.0 (1.3) 5.0 (1.3) 4.6 (1.2) 4.7 (1.3) 4.6 (1.2)
Weight male, mean (SD),
kgb
93.8 (18.5) 96.6 (18.2) 84.0 (15.7) 93.6 (18.2) 86.8 (18.9) 96.5 (18.9)
Weight female, mean
(SD), kgb
82.2 (18.1) 85.0 (17.8) 72.1 (15.9) 81.8 (17.5) 76.8 (18.4) 85.1 (17.6)
DM duration, mean
(SD), yc
2.3 (3.0) 1.5 (2.3) 2.1 (3.0) 3.5 (3.1) 5.2 (4.3) 5.6 (3.8)
LVD prior, n (%)d 13 742 (13.1) 6491 (11.1) 3070 (18.9) 2816 (12.2) 878 (22.3) 487 (14.4)
Cancer, n (%) 8693 (8.3) 4373 (7.5) 1926 (11.9) 1766 (7.7) 394 (10.0) 234 (6.9)
Vision problems prior, n (%) 24 170 (23.0) 13 409 (22.9) 4027 (24.8) 5122 (22.2) 880 (22.3) 732 (21.7)
Creatinine 130 mol/L
prior, n (%)e
4765 (4.5) 1151 (2.2) 2198 (17.2) 634 (3.1) 684 (21.1) 98 (3.3)
Prior antihypertensives,
n (%)
72 686 (69.1) 39 521 (67.5) 11 348 (70.0) 16 422 (71.2) 2852 (72.3) 2543 (75.2)
Prior lipid-lowering
drugs, n (%)
56 408 (53.7) 29 376 (50.2) 7285 (44.9) 14 807 (64.2) 2448 (62.1) 2492 (73.7)
Prior antiplatelet drugs,
n (%)
45 196 (43.0) 22 691 (38.8) 7415 (45.7) 11 156 (48.4) 2063 (52.3) 1871 (55.4)
Prior aspirin in previous
year, n (%)
44 594 (42.4) 22 406 (38.3) 7293 (45.0) 11 032 (47.9) 2020 (51.2) 1843 (54.5)
Charlson Index, mean (SD) 1.8 (1.2) 1.6 (1.1) 2.1 (1.5) 1.9 (1.2) 2.4 (1.6) 2.0 (1.3)
GP contacts prior year,
mean (SD)
11.7 (10.1) 10.9 (9.4) 12.7 (11.1) 11.7 (9.7) 16.8 (13.2) 14.0 (10.9)
Abbreviations: DM, diabetes mellitus; GP, general practitioner; SBP, systolic blood pressure; TC, total cholesterol.
a At index date (treatment initiation).
b Nearest value to index date.
c Duration of diabetes mellitus from presentation to index date.
d Clinically emergent large-vessel disease before the index date (defined by Action to Control Cardiovascular Risk in Diabetes trial criteria).
e Any record of a serum creatinine test result greater than 130 mol/L prior to the index date; proportion refers to numbers with valid creatinine
measurement.
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Model adjustment
The following baseline covariates were identified a priori and
included in all models: age, gender, systolic blood pressure,
HbA1c, total cholesterol, serum creatinine, body mass index,
smoking status, other risk-factor management (antihyperten-
sive, lipid-lowering, and antiplatelet therapy), duration of dia-
betes, prior history of cancer, LVD,microvascular disease, num-
ber of contacts with the general practitioner in the year prior to
the index date, and the Charlson comorbidity index.
Analysis was performed using multiple imputation for miss-
ing values using logistic and linear regression as appropriate to
the target variable.
Results
Subjects and baseline characteristics
There were 105 123 relevant, glucose-lowering regi-
men exposure periods for 84 622 individual cases, with a
total of 298 530 person-years’ follow-up. Baseline char-
acteristics are characterized in Table 1. There were ex-
pected differences between the groups in terms of demo-
graphics andbaseline characteristics. Patients treatedwith
sulfonylurea monotherapy were older [68.1 years com-
pared with 61.9 years overall (P  .001)] and a greater
proportionhad a serumcreatinine level above 130mol/L
[17.2% vs 4.5% overall (P  .001)]. Those treated with
insulin either asmonotherapyor in combinationwithmet-
formin had higher baseline HbA1c (9.5% and 9.6%, re-
spectively, compared with 8.7% overall). There were also
differences in baseline morbidity, with subjects treated
with sulfonylureamonotherapy and insulin monotherapy
having a greater prevalence of prior LVD (18.9% and
22.3%, respectively, vs 13.1% overall).
Crude event rates
The number of recorded events and the crude rates for
the selected outcomes are listed in Table 2. Overall, the
Table 2. Crude Event Frequency and Event Rate per 1000 Person-Years, by Glucose-Lowering Regimen
Parameter
Primary
End Point
All-Cause
Mortality MACEa Cancerb
Eye
Complicationsc Neuropathy
Renal
Complications
Combined
Microvascular
All subjects
Events 8252 6630 2558 4029 8190 3633 1050 10 322
Rate 35.6 22.2 10.0 15.0 41.4 12.8 3.4 52.5
Metformin monotherapy
Events 5929 2434 1936 2581 3637 1690 263 4515
Rate 36.6 14.9 11.6 15.6 32.6 10.7 1.5 42.0
Metformin  sulfonylurea
Events 1626 1152 538 818 2250 825 149 1716
Rate 31.4 17.6 9.5 13.8 52.7 13.4 2.2 65.1
Insulin  metformin
Events 281 184 87 173 396 247 28 2562
Rate 30.8 15.7 8.8 16.1 53.8 23.5 2.3 63.7
Sulfonylurea monotherapy
Events 2088 2269 624 805 1387 579 435 585
Rate 67.7 50.7 17.6 20.9 48.6 13.6 9.6 88.2
Insulin monotherapy
Events 518 591 164 231 520 292 175 464
Rate 58.9 46.0 16.7 20.3 66.4 25.9 13.5 70.2
a Nonfatal MI, nonfatal ischemic or hemorrhagic stroke, or cardiovascular death.
b Including solid-tumor and hematological forms.
c Including blindness, retinopathy, and glaucoma.
Table 3. aHRs by Glucose-Lowering Regimen
Parameter
Primary End Point All-Cause Mortality
aHR 95% CI P Value aHR 95% CI P Value
Metformin monotherapy (referent) 1.000 1.000
Sulfonylurea monotherapy 1.436 1.354 1.523 .0001 1.749 1.643 1.863 .0001
Metformin  sulfonylurea 1.024 0.963 1.090 .4454 1.100 1.022 1.184 .0111
Insulin monotherapy 1.808 1.630 2.005 .0001 2.197 1.983 2.434 .0001
Insulin  metformin 1.309 1.150 1.491 .0001 1.344 1.148 1.575 .0002
Eye Complications Neuropathy
Metformin monotherapy (referent) 1.000 1.000
Sulfonylurea monotherapy 1.026 0.960 1.097 .4514 1.127 1.011 1.256 .0303
Metformin  sulfonylurea 1.208 1.143 1.278 .0001 1.214 1.102 1.337 .0001
Insulin monotherapy 1.171 1.057 1.298 .0026 2.146 1.832 2.514 .0001
Insulin  metformin 1.181 1.055 1.321 .0037 2.318 1.964 2.736 .0001
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mortality rate was 22.2 deaths per 1000 person-years,
whereas the rates forMACEand incident cancerwere10.0
and 15.0 events per 1000 person-years, respectively. The
rate for the primary end point was 35.6 events per 1000
person-years. For specific regimens, crude mortality rates
were notably higher for sulfonylurea monotherapy (50.7
deaths per 1000 person-years) and insulin monotherapy
(46.0deathsper1000person-years).Thiswasalso true for
the primary end point, with respective rates of 67.7 and
58.9 events per 1000 person-years.
Adjusted relative outcome by glucose-lowering
regimen
The likelihoodof adverse events varied byoutcome and
by glucose-lowering regimen. Table 3 lists the overall ad-
justed hazard ratios (aHRs) for each end point for each
regimen, andwithin the sameCoxmodel usingmetformin
monotherapy as the reference regimen. For mortality,
there were increased aHRs for insulinmonotherapy (aHR
2.197, 95% CI 1.983–2.434), sulfonylurea monotherapy
(1.749, 95%CI1.643–1.863), and insulin plusmetformin
combination therapy (1.344, 95% CI 1.148–1.575).
For MACE, there were increased hazard ratios for
all therapies vs metformin: sulfonylurea monotherapy
(1.392, 95% CI 1.251–1.549), metformin plus sulfonyl-
urea (1.095, 95% CI 0.982–1.221), insulin monotherapy
(1.736, 95%CI1.441–2.092), and insulin plusmetformin
(1.217, 95% CI 0.963–1.539). For MI, all therapies had
higher aHRs: sulfonylurea monotherapy (1.648, 95% CI
1.402–1.938), insulin monotherapy (1.954, 95% CI
1.479–2.583), and insulin plus metformin (1.438, 95%
CI 1.027–2.014). For cerebrovascular events, sulfonyl-
urea (1.237, 95% CI 1.101–1.391), metformin plus sul-
fonylurea (1.130, 95% CI 1.006–1.269), and insulin
monotherapy (1.432, 95% CI 1.159–1.771) all had in-
creased aHRs vs metformin. For cancer, there were
increased aHRs for sulfonylurea (1.097, 95% CI 1.004–
1.199), insulin monotherapy (1.437, 95% CI 1.234–
1.674), and insulin plus metformin (1.394, 95% CI
1.176–1.651).
For the primary end, point, there were significantly in-
creasedaHRsforsulfonylureamonotherapy(1.436,95%CI
1.354–1.523), insulinmonotherapy (1.808,95%CI1.630–
2.005), and insulin plus metformin (1.309, 95% CI
1.150–1.491).
For visual end points, metformin plus sulfonylurea
(1.208, 95% CI 1.143–1.278), insulin monotherapy
(1.171, 95% CI 1.057–1.298), and insulin plus met-
formin (1.181, 95% CI 1.055–1.332) all had increased
aHRs compared with metformin monotherapy. For the
neuropathy end point, metformin plus sulfonylurea
(1.214, 95% CI 1.102–1.337), insulin monotherapy
(2.146, 95% CI 1.832–2.514), and insulin plus met-
formin (2.318, 95% CI 1.964–2.736) all had increased
aHRs compared with metformin monotherapy. For re-
nal end points, sulfonylurea (2.632, 95% CI 2.198–
3.151), metformin and sulfonylurea (1.389, 95% CI
1.122–1.720), insulin monotherapy (3.504, 95% CI
2.718–4.518), and insulin plusmetformin (1.667, 95%
CI 1.091–2.547) all had increased aHRs comparedwith
metformin monotherapy.
Metformin vs insulin monotherapy subgroup
analysis
For each end point, aHRs for each of the six combi-
nations of baseline HbA1c (low: 8.4%, medium:
8.4% and 10.2%, high: 10.2%) and morbidity
(low: Charlson index 1, high: Charlson index 1) are
illustrated in Figure 1. For mortality, the aHRs were
increased across all six categories with a range from
1.897 [95% CI 1.541–2.336 (low HbA1c, high mor-
bidity)] to 2.776 [95% CI 1.823–4.228 (low HbA1c,
low morbidity)]. For the primary end point, all aHRs
Table 3. Continued
Parameter
MACE Cancer
aHR 95% CI P Value aHR 95% CI P Value
Metformin monotherapy (referent) 1.000 1.000
Sulfonylurea monotherapy 1.392 1.251 1.549 .0001 1.097 1.004 1.199 .0410
Metformin  Sulfonylurea 1.095 0.982 1.221 .1035 0.956 0.877 1.043 .3120
Insulin monotherapy 1.736 1.441 2.092 .0001 1.437 1.234 1.674 .0001
Insulin  metformin 1.217 0.963 1.539 .1001 1.394 1.176 1.651 .0001
Renal Complications Combined Microvascular
Metformin monotherapy (referent) 1.000 1.000
Sulfonylurea monotherapy 2.632 2.198 3.151 .0001 1.097 1.033 1.165 .0024
Metformin  sulfonylurea 1.389 1.122 1.720 .0026 1.214 1.153 1.279 .0001
Insulin monotherapy 3.504 2.718 4.518 .0001 1.363 1.240 1.498 .0001
Insulin  metformin 1.667 1.091 2.547 .0182 1.326 1.196 1.470 .0001
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were significant with the exception of high morbidity,
high HbA1c. The range was 1.469 [95% CI 0.978–
2.206 (high HbA1c, high morbidity)] to 2.644 [95%CI
1.896–3.687 (medium HbA1c, low morbidity)].
Insulin monotherapy vs all alternative
glucose-lowering regimens
In order to address criticism that metformin mono-
therapy was used as the comparator regimen throughout,
Figure 1. Adjusted hazard ratios for insulin monotherapy vs metformin monotherapy. Baseline HbA1c was as follows: low, 8.4; medium, 8.4
and 10.2; high, 10.2. Morbidity was as follows: low, Charlson index  1; high, Charlson index  1.
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we have also provided for the primary endpoint a direct,
adjusted comparison between each individual glucose-
lowering regimenand insulinmonotherapy (Figure 2). For
the primary end point and after excluding the other reg-
imens from the model (thus potentially different aHRs in
the proportional hazards model), insulin monotherapy
was consistently associated with increased risk compared
with metformin monotherapy (1.778, 95% CI 1.575–
2.007), sulfonylurea monotherapy (1.160, 95% CI
1.025–1.313), metformin plus sulfonylurea combination
therapy (1.716, 95% CI 1.527–1.930), and insulin plus
metformin combination therapy (1.507, 95% CI
1.277–1.780).
Discussion
This epidemiological study demonstrated an association
forpeoplewithT2DMbetween treatmentwith exogenous
insulin and worse outcomes for cardiovascular events,
stroke, cancer, neuropathy, eye complications, renal dis-
ease, and all-cause mortality compared with patients
treated with metformin monotherapy. Furthermore, sul-
fonylurea monotherapy resulted in increased hazard for a
range of outcomes, although combina-
tion therapy with metformin attenu-
ated risk to some extent. Insulin mono-
therapy resulted in worse outcome vs
all other regimens for the primary end
point and all-cause mortality.
These data are consistent with a va-
riety of previous evidence observing
worse outcomes in people with T2DM
treatedwith insulin. For instance, there
are data from large, population-based,
observational studies that have found
an association between increasing insu-
lin use and serious events (13–17, 21,
22), although, to date, there has been a
relative dearth of long-term clinical
trial data evaluating the risk–benefit
profile of exogenous insulin in T2DM.
The Diabetes and Insulin-Glucose
Infusion in Acute Myocardial Infarc-
tion (DIGAMI)-1 andDIGAMI-2 trials
examined outcome effects of different
glucose-lowering regimens in people
withT2DMafterMI. In theDIGAMI-1
study (25), insulin-based regimens com-
pared with other glucose-lowering
management improved survival in pa-
tientswith acuteMI.However, theben-
efit of insulin was never confirmed in
DIGAMI-2 (26). In this second study, patients with
T2DM and MI were randomized to three different glu-
cose-lowering strategies, with no significant differences in
the total mortality or cardiovascular morbidity rates be-
tween glucose-lowering strategies. The interpretation
of the discrepant outcomes between DIGAMI-1 and
DIGAMI-2was that the second study, unlike the first, had
no difference in glucose control between the treatment
arms. Indeed, there was a trend toward diverging mortal-
ity and morbidity rates to the benefit of patients without
insulin treatment by the end of DIGAMI-2. A higher rate
of nonfatal reinfarction and stroke occurred among pa-
tients receiving insulin. Furthermore, an observational
analysis of long-term mortality in the DIGAMI-2 cohort
has suggested that long-term, insulin-based therapy may
be linked to not only an increase in nonfatal cardiovascu-
lar events but also tomore noncardiovascular deaths (26).
Exogenous insulin is initiatedwith a view to improving
glucose control and is usually commenced at a late stage in
the natural history of the disease, with recent data illus-
trating a mean HbA1c at insulin initiation in Europe of
approximately 10% (27). There is some evidence that
tight glycemic control initiated soon after diagnosis is as-
Figure 2. Adjusted survival curves for each specific regimen vs insulin monotherapy for the
primary end point. Blue line indicates insulin monotherapy. Red line indicates comparator.
Model specification includes the following: age, gender, smoking history, prior primary care
contacts, and Charlson index.
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sociated with long-term outcome benefits, but data from
studies such as DIGAMI-2 and Action to Control Cardio-
vascular Risk in Diabetes (ACCORD) (28) suggest that
undoubted improvement in glucose control using insulin
maynotoffset related risks.TheOutcomeReductionWith
Initial Glargine Intervention (ORIGIN) study has consid-
ered outcomes associated with early insulinization, com-
paring the impact of targeting a fasting plasmaglucose less
than 5.3 mmol/L with insulin glargine vs usual care over
an estimated five-year treatment period in people with
established cardiovascular disease coupled with glucose
intolerance or early T2DM (29). This study found no dif-
ference in cardiovascular, mortality, or cancer outcomes
between patients treated with insulin and those treated
with standard care. However, of those patients treated
according to standard care, 47% were treated with a reg-
imen including sulfonylurea and 11% with a regimen in-
cluding insulin.
There are multiple potential mechanisms that could
link exogenous insulinwith adverse outcomes such as car-
diovascular end points and cancer in people with T2DM.
Insulin initiation and titration result in weight gain in the
region of 2 kg per 1% reduction achieved in HbA1c, an
effect thatmay exacerbate both cancer and cardiovascular
risk. Insulin is a growth factor known to have atherogenic
and mitogenic effects, which may provide an adaptive ad-
vantage formalignant foci andpotentiate thedevelopment
of atherosclerotic vascular disease. Indeed, endogenous
hyperinsulinemia has been linked to an increase in cancer
incidence in people without diabetes (30), whereas epidemi-
ological data have linked exogenous insulin therapywith an
increased cancer incidence inpeoplewithT2DM(22).These
events will then result in increased mortality risk.
One plausible explanation for the increased risk of mi-
crovascular events with insulin exposure observed here
and in other populations (31) is the hemodynamic effect of
insulin itself. Insulin is known to induce vasodilation (32)
mediated via endogenous arteriolar nitric oxide pathways
(33).Thesechanges increasepulsepressureanddecreaseaug-
mentation index (34), exposing the microvasculature to in-
creased pulsatility, which causes irreversible mechanical
damage leading to retinal and renal sequelae (31, 35). Fur-
thermore, excessive insulin exposure may result in excessive
nitric oxide production, resulting in oxidative stress (36).
There are various limitations inherent in our study. Fol-
low-up in this study was relatively short (approximately
three years), reflecting the duration that patients remained
on a single therapeutic regimen. This may be less than the
latency period for certain conditions tomanifest as clinical
events, particularly for some cancers.
Observational studies like this are susceptible to a num-
ber of common flaws (37), the one most relevant to this
study being the possibility of confounding by indication.
Because diabetes is a progressive disease, therapy choice
will reflect this progression such that patientswhoarewell
controlled on first-line therapy, usually metformin, will
remain on this therapy,whereas thosewho fail in the sense
of increased levels of glycemia or development of compli-
cationswill be treatedmore aggressivelywith the addition
of other treatment options. Metformin is also contraindi-
cated in patients with moderate renal disease. It is evident
from the baseline characteristics (Table 1) that there are
significant differences between the cohorts in terms of
prior vascularmorbidity (metformin11.1%vs18.9%and
22.3% for sulfonylureas and insulin, respectively) and
other demographic andbiochemicalmarkers. Equally, pa-
tients treated with insulin had higher HbA1c than other
groups, indicating increased insulin resistance, which
would predict worse outcomes.
To partly address this issue, we have adjusted ourmod-
els with a wide range of potentially confounding covari-
ates, but these results must be considered with the caveat
of residual confounding both within the candidate cova-
riates and those factors that could not be represented
within our models.
The use of routine data for research purposes raises
questions over the accuracy of diagnostic and other infor-
mation. Studies involving GPRD have tended to conclude
that the quality of recording is good (38), but there re-
mains potential for error. For the specific case of diabetes,
there remains the possibility of misclassification between
type 1 and type 2 diabetes. This is due to either nonspecific
codes being used or type 2 patients being incorrectly re-
corded as type 1 and vice versa. This is compoundedby the
use of insulin-dependent diabetes and non-insulin-depen-
dent diabetes as synonyms for type 1 and type 2 diabetes,
respectively, being incorrectly applied.Wehavedeveloped
a series of decision rules to classify patients in whom there
is some doubt over diabetes type using diagnostic, demo-
graphic, and therapy criteria, but we accept that there is
still room for error. This error will not be random but
likely biased toward those patients treated with insulin
monotherapy.
We used metformin monotherapy as the referent glu-
cose-lowering regimen in the Cox models; however, all
regimens were compared in adjusted analyses within the
same models. In addition, we compared all therapies in-
dividually with insulin monotherapy as the referent. Our
findings were generally consistent across a range of pri-
mary and individual outcomes. The source of these data
(GPRD) is highly regarded, and the data are from real life,
with almost 300 000 person-years’ follow-up. GPRD is a
proprietary data source so others can replicate this anal-
ysis. In general, the patterns elicited were consistent and
J Clin Endocrinol Metab, February 2013, 98(2):668–677 jcem.endojournals.org 675
the order of magnitude of the adjusted hazard ratios
and the dispersion of their CIs often striking. Therefore,
although this analysis is admittedly imperfect—like all ep-
idemiological studies—these data should raise justifiable
concerns in relation to the optimal use of exogenous in-
sulin therapy in clinical practice.
Although these datamay raise questions around the use
of insulin in people with T2DM, data from large con-
trolled clinical trials such as ACCORD (28) have demon-
strated no specific adverse safety signal with respect to
insulin therapy. However, the design of such studies,
largely protocol-led and focusing on glycemic-control tar-
gets and multiple therapies, does not readily lend itself to
the specific evaluation of adverse events that may be as-
sociated with a particular therapy.
Exogenous insulin is the longest-established blood-glu-
cose-lowering therapy and produces large reductions in
blood-glucose levels; it can be life-saving for patients that
absolutely require insulin-replacement therapy, such as
those with type 1 diabetes. Nevertheless, there is a clear
need to review the way in which exogenous insulin is used
in people with type 2 diabetes and to establish in detail the
risk–benefit profile at differing stages of the natural his-
tory of the disease and in phenotypically different
sub-groups.
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